尤文肉瘤化疗减量与延迟对无事件生存的影响:EE2012试验回顾分析
该研究基于Euro Ewing 2012试验数据,采用目标试验模拟和倾向评分方法,评估VDC/IE诱导方案中减量和时间延迟对无事件生存(EFS)的因果效应。结果显示减量对EFS无显著损害(HR=0.69),时间延迟影响亦不显著(HR=1.02),提示按方案进行的毒性管理调整不显著影响预后。
要点
- 减量对EFS无显著不利影响,HR=0.69。
- 时间延迟对EFS影响轻微且不显著,HR=1.02。
- 按方案调整化疗剂量与时间不显著损害患者预后。
核心结论
- 按方案进行的减量和时间延迟对EFS无显著不利影响。
研究设计与样本
- 基于Euro Ewing 2012试验的回顾性分析,采用目标试验模拟和倾向评分方法。
主要发现
- 减量对EFS的HR=0.69(95%CI 0.39-1.24),无统计学显著性。
- 时间延迟对EFS的HR=1.02(95%CI 0.90-1.15),无统计学显著性。
- 减量随时间的EFS获益呈有利趋势,延迟增加则呈轻微临床不利趋势。
临床怎么用
- 为毒性管理而按方案调整化疗剂量和时间不显著损害预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment adjustments are commonly implemented during chemotherapy to mitigate toxicity, but their impact on event-free survival (EFS) remains poorly understood. This study aims to evaluate the causal effect of dose reductions and time delay during the VDC/IE induction regimen (vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide) on EFS in patients with Ewing Sarcoma. METHODS: Chemotherapy administration data from the Euro Ewing 2012 (EE2012) trial were used to emulate a target trial, where the target exposures were a binary indicator for total dose reduction and a measure of continuous time delay in treatment duration. Propensity score methods were applied to the original EE2012 population to create a target pseudo-population in which treatment adjustments could be regarded as if randomized. A Cox marginal structural model was fitted to the pseudo-population, and EFS benefit compared to the reference strategy (no reduction; no delay) was estimated for different treatment-adjustment profiles, along with bootstrap confidence intervals. RESULTS: Dose reduction was found protective for EFS (HR=0.69; 95%CI: [0.39; 1.24]), whereas time delay showed a slightly detrimental effect (HR=1.02; 95%CI: [0.90; 1.15]), both non-statistically significant. In terms of EFS benefits, dose reduction exhibited a favourable trajectory over time, while a mild trend toward a clinical disadvantage was observed as time delay increased. Results provide no evidence that reductions in dose and delays to administration, when implemented according to protocol, have a significant detrimental effect on EFS outcome. CONCLUSIONS: The findings provide reassurance that treatment adjustments for toxicity management do not substantially compromise patient prognosis.
引用
- Liu Y, Fiocco M, Kirton L, et al. Assessing the effect of chemotherapy dose reductions and time delay on event-free survival in Ewing Sarcoma: A retrospective analysis of the Euro Ewing 2012 trial. Eur J Cancer. 2026. PMID: 42766959. doi:10.1016/j.ejca.2026.117057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。